首頁 > 市場調查報告書 > 製藥

感染疾病

全球頭孢曲松市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1346830

全球頭孢曲松市場研究報告 - 2023 年至 2030 年行業分析、規模、佔有率、成長、趨勢和預測

Global Ceftriaxone Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年08月01日 | 出版商:

Value Market Research | 英文 125 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球頭孢曲松市場需求預計將從 2022 年的 30 億美元增至 2030 年的近 39.5 億美元，2023-2030 年研究期間年複合成長率為 3.5%。

頭孢曲松是一種廣譜抗生素藥物，屬於頭孢菌素類藥物。它可以治療身體各個部位的細菌感染。頭孢菌素是一組與青黴素密切相關的抗生素，用於通過乾擾細菌細胞壁的合成來對抗細菌感染，最終導致細菌被破壞。

市場動態：

細菌感染（包括抗生素耐藥菌株）的流行極大地增加了對這種廣譜抗生素的需求。對肺炎和敗血症等嚴重細菌感染的全球健康擔憂也刺激了市場。頭孢曲鬆在醫院環境中用於術後預防和治療嚴重感染的應用增加了其需求。傳染病的爆發和全球旅行的增加凸顯了對頭孢曲松等有效抗生素的需求。此外，其在治療耐藥性淋病方面的關鍵作用也帶來了持續的需求。製藥行業的持續成長、研發工作以及對監管指南的遵守共同影響了頭孢曲鬆的可及性和可用性。

該研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對頭孢曲松全球市場的每個細分市場進行了包容性評估。頭孢曲松行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲頭孢曲松市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。頭孢曲松酮市場的主要參與者包括 Hikma Pisarmaceuticals plc、齊魯製藥有限公司、諾華公司、Baxter International Inc.、Aurobindo Pharma、ACS DOBFAR SPA、Orchid Pharma、Nectar Lifesciences Ltd.、Lupin Pharmaceuticals inc.。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史和預測數據銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史和預測數據銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測數據銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：頭孢曲松公司的競爭格局

頭孢曲松鈉市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市場佔有率分析
市場集中度
Hikma Pisarmaceuticals plc

公司簡介
公司收入
產品
最近的發展

Qilu Pharmaceutical Co. Lt

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Baxter International Inc.

公司簡介
公司收入
產品
最近的發展

Aurobindo Pharma

公司簡介
公司收入
產品
最近的發展

ACS DOBFAR SPA

公司簡介
公司收入
產品
最近的發展

Orchid Pharma

公司簡介
公司收入
產品
最近的發展

Nectar Lifesciences Ltd.

公司簡介
公司收入
產品
最近的發展

Lupin Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112112049

The global demand for Ceftriaxone Market is presumed to reach the market size of nearly USD 3.95 BN by 2030 from USD 3 BN in 2022 with a CAGR of 3.5% under the study period 2023 - 2030.

Ceftriaxone is a broad-spectrum antibiotic medication belonging to the class of drugs known as cephalosporins. It treats bacterial infections in various parts of the body. Cephalosporins are a group of antibiotics closely related to penicillins and are used to combat bacterial infections by interfering with the bacteria's cell wall synthesis, ultimately leading to their destruction.

MARKET DYNAMICS:

The prevalence of bacterial infections, including antibiotic-resistant strains, has significantly contributed to the demand for this broad-spectrum antibiotic. Global health concerns surrounding serious bacterial infections such as pneumonia and septicemia have also fueled the market. Ceftriaxone's application in hospital settings for post-surgical prophylaxis and treatment of severe infections has heightened its demand. Outbreaks of infectious diseases and increased global travel have underscored the need for effective antibiotics like Ceftriaxone. Furthermore, its crucial role in treating drug-resistant gonorrhea has sustained demand. Ongoing pharmaceutical industry growth, research and development efforts, and adherence to regulatory guidelines have collectively influenced the accessibility and availability of Ceftriaxone.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ceftriaxone. The growth and trends of ceftriaxone industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the ceftriaxone market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Indication

Urinary Tract Infections
Intra-Abdominal Infections
Endocarditis
Acute Bacterial Otitis Media
Meningitis
Pneumonia
Others

By Distribution Channel

Hospital Pharmacies
Retal Pharmacies
Online Pharmacies

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Ceftriaxone market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Ceftriaxone market include Hikma Pisarmaceuticals plc, Qilu Pharmaceutical Co. Lt, Novartis AG, Baxter International Inc., Aurobindo Pharma, ACS DOBFAR S.P.A, Orchid Pharma, Nectar Lifesciences Ltd., Lupin Pharmaceuticals inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . CEFTRIAXONE - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Indication
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CEFTRIAXONE MARKET ANALYSIS BY INDICATION

5.1 Overview by Indication
5.2 Historical and Forecast Data
5.3 Analysis by Indication
5.4 Urinary Tract Infections Historic and Forecast Sales by Regions
5.5 Intra-abdominal Infections Historic and Forecast Sales by Regions
5.6 Endocarditis Historic and Forecast Sales by Regions
5.7 Acute Bacterial Otitis Media Historic and Forecast Sales by Regions
5.8 Meningitis Historic and Forecast Sales by Regions
5.9 Pneumonia Historic and Forecast Sales by Regions
5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL CEFTRIAXONE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
6.5 Retal Pharmacies Historic and Forecast Sales by Regions
6.6 Online Pharmacies Historic and Forecast Sales by Regions

7 . GLOBAL CEFTRIAXONE MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE CEFTRIAXONE COMPANIES

8.1. Ceftriaxone Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF CEFTRIAXONE INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Hikma Pisarmaceuticals plc
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Qilu Pharmaceutical Co. Lt
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Baxter International Inc.
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Aurobindo Pharma
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. ACS DOBFAR S.P.A
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Orchid Pharma
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Nectar Lifesciences Ltd.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Lupin Pharmaceuticals Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments